Schizophrenia Research
Volume 71, Issue 1 , Pages 137-144 , 1 November 2004

Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients

  • Peter L. Zhang

      Affiliations

    • BJC Behavioral Health Clinics, 1430 Olive St, Saint Louis, MO 63110, USA
    • Department of Psychiatry, Washington University, 4559 Scott Avenue, Saint Louis, MO 63110, USA
    • ,
  • Juan M. Santos

      Affiliations

    • Department of Neurology, Washington University, 660 S. Euclid Avenue, Saint Louis, MO 63110, USA
    • ,
  • John Newcomer

      Affiliations

    • BJC Behavioral Health Clinics, 1430 Olive St, Saint Louis, MO 63110, USA
    • Department of Psychiatry, Washington University, 4559 Scott Avenue, Saint Louis, MO 63110, USA
    • ,
  • Barbara A. Pelfrey

      Affiliations

    • BJC Behavioral Health Clinics, 1430 Olive St, Saint Louis, MO 63110, USA
    • ,
  • Mark C. Johnson

      Affiliations

    • BJC Behavioral Health Clinics, 1430 Olive St, Saint Louis, MO 63110, USA
    • Department of Psychiatry, Washington University, 4559 Scott Avenue, Saint Louis, MO 63110, USA
    • ,
  • Gabriel A. de Erausquin

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Psychiatry and Neurology, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8134 Saint Louis, MO 63110, USA. Tel.: +1-314-362-5186; fax: +1-314-747-9283.
    • BJC Behavioral Health Clinics, 1430 Olive St, Saint Louis, MO 63110, USA
    • Department of Psychiatry, Washington University, 4559 Scott Avenue, Saint Louis, MO 63110, USA

Received 27 May 2003 ,Revised 4 November 2003 ,Accepted 12 November 2003.

References 

  1. Angermeyer MC, Matschinger H. Neuroleptics and quality of life. A patient survey. Psychiatr. Prax. 2000;27:48–64
  2. Awad AG, Lapierre YD, Angus C, Rylander A. The Canadian Remoxipride Group. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. J. Psychiatry Neurosci. 1997;22:244–248
  3. Collaborative Working Group on Clinical Trial Evaluations . Measuring outcome in schizophrenia: differences among the atypical antipsychotics. J. Clin. Psychiatry. 1998;59(Suppl 12):3–9
  4. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst. Rev. 2000; (1):CD001359
  5. Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics. 1998;14:97–133
  6. Foster RH, Goa KL. Olanzapine. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics. 1999;15:611–640
  7. Franz M, Lis S, Pluddemann K, Gallhofer B. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br. J. Psychiatry. 1997;170:422–425
  8. Geddes J, Freemantle N, Harrison P, Bebbington P  National Schizophrenia Guideline Development Group . A typical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 2000;321:1371–1376
  9. Gerlach J, Larsen EB. Subjective experience and mental side-effects of antipsychotic treatment. Acta Psychiatr. Scand., Suppl. 1999;395:113–117
  10. Jarema M, Konieczynska Z. Quality of life in schizophrenic patients treated with classic and “old” atypical neuroleptics. Psychiatr. Pol. 2000;34:275–288
  11. Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev. 2000; (2):CD000440
  12. Lindstrom LH. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr. Scand., Suppl. 1994;380:74–76
  13. Malla AK, Norman RM, Kotteda V, Zirul S. Switching from therapy with typical antipsychotic agents to risperidone: long term impact on patient outcome. Clin. Ther. 1999;21:806–817
  14. Norman RM, Malla AK, McLean T, Voruganti LP, Cortese L, McIntosh E, et al. The relationship of symptoms and level of functioning in schizophrenia to general well being and the Quality of Life Scale. Acta. Psychiatr. Scand. 2000;102:303–309
  15. Revicki DA. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr. Res. 1999;35:S101–S109
  16. Revicki DA. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Curr. Opin. Investig. Drugs. 2001;2:110–117
  17. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual. Life Res. 1999;8:417–426
  18. Ritsner M, Ponizovsky A, Endicott J, Nechamkin Y, Rauchverger B, Silver H, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur. Neuropsychopharmacol. 2002;12:31–38
  19. Sajatovic M, Ramirez LF, Belton J, McCormick R. Health resource utilization and clinical outcomes with risperidone therapy in patients with serious mental illness. Compr. Psychiatry. 1999;40:198–202
  20. Schiller MJ, Shumway M, Hargreaves WA. Treatment costs and patient outcomes with use of risperidone in a public mental health setting. Psychiatr. Serv. 1999;50:228–232
  21. Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database Syst. Rev. 2000; (3):CD000967
  22. Thieda P, Beard S, Richter A, Kane J. An economic review o f compliance with medication therapy in the treatment of schizophrenia. Psychiatr. Serv. 2003;54:508–516
  23. Tunis SL. The impact of schizophrenic patient functionality on service utilization and cost. Am. J. Manag. Care. 1999;5:S583–S590
  24. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr. Res. 2002;57:201–208
  25. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am. J. Psychiatry. 1999;156:990–999
  26. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J. Clin. Psychiatry. 1996;57(Suppl. 11):53–60

PII: S0920-9964(03)00386-4

doi: 10.1016/j.schres.2003.11.005

Schizophrenia Research
Volume 71, Issue 1 , Pages 137-144 , 1 November 2004

Article Tools

* Image Usage & Resolution